(Q38943411)

English

Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

0 references

0 references

Plasmodium yoelii

1 reference

based on heuristic

inferred from title

malaria vaccine

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Mahamoud Sama Cherif

object named as

Mahamoud Sama Cherif

1

0 references

Tomoaki Kurosaki

object named as

Tomoaki Kurosaki

4

0 references

Juntra Karbwang

12

object named as

Juntra Karbwang

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

6

object named as

Mihoko Kikuchi

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

author name string

Mohammed Nasir Shuaibu

2

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Yukinobu Kodama

3

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Gideon Kofi Helegbe

5

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Akitoyo Ichinose

7

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Tetsuo Yanagi

8

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Hitoshi Sasaki

9

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Katsuyuki Yui

10

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Nguyen Huy Tien

11

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

language of work or name

0 references

publication date

15 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1998-2006

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Genetic immunization is a simple method for eliciting an immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Selection and identification of malaria vaccine target molecule using bioinformatics and DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Band 3 is a host receptor binding merozoite surface protein 1 during thePlasmodium falciparuminvasion of erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

A co-ligand complex anchors Plasmodium falciparum merozoites to the erythrocyte invasion receptor band 3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Proteases involved in erythrocyte invasion by the malaria parasite: function and potential as chemotherapeutic targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Gaa1p and gpi8p are components of a glycosylphosphatidylinositol (GPI) transamidase that mediates attachment of GPI to proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Early events in glycosylphosphatidylinositol anchor addition. substrate proteins associate with the transamidase subunit gpi8p

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Database resources of the National Center for Biotechnology Information: 2002 update

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Ternary complexes of pDNA, polyethylenimine, and gamma-polyglutamic acid for gene delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Mechanisms of cellular uptake and intracellular trafficking with chitosan/DNA/poly(γ-glutamic acid) complexes as a gene delivery vector.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Design opportunities for actively targeted nanoparticle vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Potential of nanoparticulate drug delivery systems by intranasal administration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

On the efficacy of malaria DNA vaccination with magnetic gene vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Networking at the level of host immunity: immune cell interactions during persistent viral infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Immune recognition of Plasmodium-infected erythrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Immune mechanisms in malaria: new insights in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Vaccine adjuvants: current challenges and future approaches.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Type I interferons as vaccine adjuvants against infectious diseases and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Immunostimulatory capacity of DNA vaccine vectors in porcine PBMC: a specific role for CpG-motifs?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

CpG motifs are efficient adjuvants for DNA cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Costimulatory molecules as adjuvants for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

DNA vaccines: improving expression of antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Immunological properties of engineered nanomaterials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Nanoparticles and the immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Mechanistic study of transfection of chitosan/DNA complexes coated by anionic poly(γ-glutamic acid).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Antigen presentation and T cell stimulation by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

CD11c(high )dendritic cells are essential for activation of CD4+ T cells and generation of specific antibodies following mucosal immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Regulatory activity of autocrine IL-10 on dendritic cell functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Clan CD cysteine peptidases of parasitic protozoa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.01.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2014.01.005

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38943411&oldid=1878916467"